サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1413893

がん性疼痛管理市場：薬剤タイプ、投与経路、用途、最終用途別-2024～2030年の世界予測

Cancer Pain Management Market by Drug Type (Nerve Blockers, Non-Opioids, Opioids), Route of Administration (Oral, Parental), Application, End-Use - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 189 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.94円
がん性疼痛管理市場：薬剤タイプ、投与経路、用途、最終用途別-2024～2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 189 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん性疼痛管理市場規模は2023年に74億2,000万米ドルと推定され、2024年には78億6,000万米ドルに達し、CAGR 6.09%で2030年には112億3,000万米ドルに達すると予測されます。

がん性疼痛管理の世界市場

主要市場の統計
基準年[2023年] 74億2,000万米ドル
予測年[2024年] 78億6,000万米ドル
予測年[2030年] 112億3,000万米ドル
CAGR（%） 6.09%
がん性疼痛管理 Market-IMG1

がん性疼痛管理とは、がんやその治療に伴う痛みを和らげるために採用される手法や手順を指します。この集学的アプローチは患者のニーズに合わせて行われ、がん患者の生活の質を向上させるための様々な方法が含まれます。がんに関連した疼痛管理に用いられる戦略には、鎮痛薬やオピオイドなどの薬理学的治療と、理学療法、心理的支援、補完療法などの非薬理学的介入があります。がん性疼痛の効果的な管理は、患者の快適さ、機能、そして全体的な幸福に直接影響するため、極めて重要です。がんの有病率の上昇、高齢化、技術の進歩、規制の効率化、患者の意識の高まりにより、がん性疼痛管理の必要性は向上しています。しかし、オピオイド危機、副作用、全身的な医療格差、コスト障壁、包括的な疼痛管理知識の欠如に起因する問題は、市場の成長を阻害する可能性があります。とはいえ、この領域における新たなビジネスチャンスは、精密ドラッグデリバリー技術、非オピオイド治療の採用拡大、統合デジタルヘルスツール、補完代替療法の可能性にあります。イノベーションと事業拡大は、非中毒性鎮痛薬の研究、ドラッグデリバリーメカニズムの強化、薬理遺伝学、戦略的提携によって推進されています。

地域別洞察

患者中心のケアモデルと包括的な疼痛管理の重視により、南北アメリカでは先進的ながん性疼痛管理の枠組みが構築されています。高い医療支出と幅広い保険適用により、疼痛管理ソリューションの大幅な導入が可能です。地域の医療システムは、がん患者に対する実質的なサポートを提供しており、その中には疼痛管理もケアの基本的な側面として含まれています。欧州連合（EU）諸国は、多様な医療制度と国ごとの政策の違いにより、がん性疼痛管理のアプローチに大きなばらつきが見られます。中東・アフリカ地域は、経済資源の不均質性が顕著であり、それががん性疼痛管理の利用可能性と質に直接影響しています。急速に拡大するアジア太平洋の医療システムは、がんとそれに伴う痛みの有病率の増加に適応してきました。医療インフラへの投資や医師養成プログラムは、その対応策として明らかです。適切な疼痛コントロールと在宅医療を重視する新たな政策は、アジア太平洋におけるがん性疼痛管理ソリューションの範囲を広げています。

FPNVポジショニングマトリックス

FPNVポジショニングマトリックスはがん性疼痛管理市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます。フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、がん性疼痛管理市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発とイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-がん性疼痛管理市場の市場規模と予測は？

2-がん性疼痛管理市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-がん性疼痛管理市場における技術動向と規制の枠組みは？

4-がん性疼痛管理市場における主要ベンダーの市場シェアは？

5-がん性疼痛管理市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で慢性疼痛と生活習慣病の有病率が上昇
      • 高齢者人口の増加と痛みを軽減する治療の必要性
    • 抑制要因
      • 製品リコールに伴う問題
    • 機会
      • 継続的な製品開発活動と新製品のFDA承認の増加
      • がん性疼痛治療を支援する政府の資金提供
    • 課題
      • がん性疼痛管理薬物に関連する副作用
  • 市場セグメンテーション分析
    • 薬剤タイプ：がん性疼痛の治療に対するオピオイドの適用可能性が高まる
    • 投与経路：がん性疼痛管理に対する経口薬の入手可能性の増加
    • 用途：乳がんに対するがん性疼痛管理ソリューションの新たな浸透
    • 最終用途：病院でのがん性鎮痛剤の使用増加
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 がん性疼痛管理市場：薬剤タイプ別

  • イントロダクション
  • 神経遮断薬
  • 非オピオイド
    • アセトアミノフェン
    • 非ステロイド性抗炎症薬（NSAID）
  • オピオイド
    • フェンタニル
    • モルヒネ

第7章 がん性疼痛管理市場：投与経路別

  • イントロダクション
  • 経口
  • 親子間

第8章 がん性疼痛管理市場：用途別

  • イントロダクション
  • 血液がん
  • 乳がん
  • 結腸直腸がん
  • 肺がん
  • 前立腺がん

第9章 がん性疼痛管理市場：最終用途別

  • イントロダクション
  • 在宅医療
  • 病院
  • 専門クリニック

第10章 南北アメリカのがん性疼痛管理市場

  • イントロダクション
  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋のがん性疼痛管理市場

  • イントロダクション
  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカのがん性疼痛管理市場

  • イントロダクション
  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析
    • 契約、コラボレーション、パートナーシップ
    • 新製品発売と機能強化
    • 受賞・表彰・拡大

第14章 競合ポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • AbbVie Inc.
    • Aegis Therapeutics, LLC
    • Aptinyx Inc.
    • Astellas Pharma Inc.
    • Bausch Health Companies Inc.
    • Baxter International Inc.
    • Bayer AG
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • Glaxosmithkline PLC
    • Grunenthal Group
    • Johnson & Johnson Services, Inc.
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • Sanofi SA
    • Scilex Pharmaceuticals
    • Teva Pharmaceutical Industries Ltd.
    • Trevena Inc.
  • 主要な製品ポートフォリオ

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. CANCER PAIN MANAGEMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER PAIN MANAGEMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CANCER PAIN MANAGEMENT MARKET DYNAMICS
  • FIGURE 7. CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 14. CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. CANCER PAIN MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. CANCER PAIN MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. CANCER PAIN MANAGEMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER PAIN MANAGEMENT MARKET SIZE, BY NERVE BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 9. CANCER PAIN MANAGEMENT MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 13. CANCER PAIN MANAGEMENT MARKET SIZE, BY FENTANYL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. CANCER PAIN MANAGEMENT MARKET SIZE, BY MORPHINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 16. CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. CANCER PAIN MANAGEMENT MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. CANCER PAIN MANAGEMENT MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. CANCER PAIN MANAGEMENT MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. CANCER PAIN MANAGEMENT MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. CANCER PAIN MANAGEMENT MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. CANCER PAIN MANAGEMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 152. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 158. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 164. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 170. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 176. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 182. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 188. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 194. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 200. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 206. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 212. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 218. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 224. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 230. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 236. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 242. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 248. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 254. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 260. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 266. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 278. CANCER PAIN MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 279. CANCER PAIN MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 280. CANCER PAIN MANAGEMENT MARKET LICENSE & PRICING
目次
Product Code: MRR-144C638C8F7D

[189 Pages Report] The Cancer Pain Management Market size was estimated at USD 7.42 billion in 2023 and expected to reach USD 7.86 billion in 2024, at a CAGR 6.09% to reach USD 11.23 billion by 2030.

Global Cancer Pain Management Market

KEY MARKET STATISTICS
Base Year [2023] USD 7.42 billion
Estimated Year [2024] USD 7.86 billion
Forecast Year [2030] USD 11.23 billion
CAGR (%) 6.09%
Cancer Pain Management Market - IMG1

Cancer pain management refers to the practices and procedures employed in alleviating pain associated with cancer and its treatment. This multidisciplinary approach is tailored to the patient's needs and encompasses various methods to improve the quality of life for those with cancer. The strategies used for managing cancer-related pain may include pharmacological treatments, such as analgesics and opioids, and non-pharmacological interventions, such as physical therapy, psychological support, and complementary therapies. Effective management of cancer pain is pivotal because it directly impacts a patient's comfort, functioning, and overall well-being. The rising prevalence of cancer, an aging demographic, technological advancements, regulatory efficiencies, and heightened patient awareness have improved the need for cancer pain management. However, issues arising from the opioid crisis, adverse drug reactions, systemic healthcare disparities, cost barriers, and a lack of comprehensive pain management knowledge may impede market growth. Nevertheless, emerging opportunities within this domain lie in precision drug delivery technologies, increased non-opioid treatment adoption, integrated digital health tools, and the potential of complementary and alternative therapies. Innovation and business expansion are being driven by research into non-addictive analgesics, enhancement of drug delivery mechanisms, pharmacogenetics, and strategic collaborations.

Regional Insights

Patient-centric care models and an emphasis on comprehensive pain management have led to an advanced cancer pain management framework in the Americas. High healthcare expenditure, coupled with extensive insurance coverage, allows for significant adoption of pain management solutions. The regional healthcare system provides substantial support for cancer patients, which includes pain management as a fundamental aspect of care. European Union countries exhibit high variability in cancer pain management approaches due to diverse healthcare systems and differing national policies. The Middle East and African region is characterized by significant heterogeneity in economic resources, which directly impacts the availability and quality of cancer pain management. The rapidly expanding healthcare system in the Asia-Pacific region has been adapting to the growing prevalence of cancer and its associated pain. Investment in healthcare infrastructure and physician training programs are evident response measures. New policies emphasizing adequate pain control and home-based care have broadened the scope of cancer pain management solutions in Asia-Pacific.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Pain Management Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Pain Management Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Pain Management Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Aegis Therapeutics, LLC, Aptinyx Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Eisai Co., Ltd., Eli Lilly and Company, Glaxosmithkline PLC, Grunenthal Group, Johnson & Johnson Services, Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Scilex Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Trevena Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Pain Management Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Nerve Blockers
    • Non-Opioids
      • Acetaminophen
      • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Opioids
      • Fentanyl
      • Morphine
  • Route of Administration
    • Oral
    • Parental
  • Application
    • Blood Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Prostate Cancer
  • End-Use
    • Home care
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cancer Pain Management Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Pain Management Market?

3. What are the technology trends and regulatory frameworks in the Cancer Pain Management Market?

4. What is the market share of the leading vendors in the Cancer Pain Management Market?

5. Which modes and strategic moves are suitable for entering the Cancer Pain Management Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cancer Pain Management Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic pain and lifestyle disorders worldwide
      • 5.1.1.2. Increasing geriatric population and need for pain-reducing therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing product development activities and rising FDA approvals of new products
      • 5.1.3.2. Government funding supporting cancer pain treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with cancer pain management drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Growing applicability of opioids to treat cancer pain
    • 5.2.2. Route of Administration: Growing availability of oral medications for cancer pain management
    • 5.2.3. Application: Emerging penetration of cancer pain management solutions for breast cancer
    • 5.2.4. End-Use: Elevating usage of cancer pain drugs in hospitals
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Cancer Pain Management Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Nerve Blockers
  • 6.3. Non-Opioids
    • 6.4.1. Acetaminophen
    • 6.4.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • 6.4. Opioids
    • 6.5.1. Fentanyl
    • 6.5.2. Morphine

7. Cancer Pain Management Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parental

8. Cancer Pain Management Market, by Application

  • 8.1. Introduction
  • 8.2. Blood Cancer
  • 8.3. Breast Cancer
  • 8.4. Colorectal Cancer
  • 8.5. Lung Cancer
  • 8.6. Prostate Cancer

9. Cancer Pain Management Market, by End-Use

  • 9.1. Introduction
  • 9.2. Home care
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Cancer Pain Management Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer Pain Management Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Pain Management Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player
    • 13.3.1. Agreement, Collaboration, & Partnership
      • 13.3.1.1. Esteve and Medtronic are Collaborating to Address Cancer Pain Patients' Needs
    • 13.3.2. New Product Launch & Enhancement
      • 13.3.2.1. Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
    • 13.3.3. Award, Recognition, & Expansion
      • 13.3.3.1. FDA Approves Non-Opioid Painkiller for Mild-to-Moderate Pain

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Abbott Laboratories
    • 14.1.2. AbbVie Inc.
    • 14.1.3. Aegis Therapeutics, LLC
    • 14.1.4. Aptinyx Inc.
    • 14.1.5. Astellas Pharma Inc.
    • 14.1.6. Bausch Health Companies Inc.
    • 14.1.7. Baxter International Inc.
    • 14.1.8. Bayer AG
    • 14.1.9. Biogen Inc.
    • 14.1.10. Boehringer Ingelheim International GmbH
    • 14.1.11. Eisai Co., Ltd.
    • 14.1.12. Eli Lilly and Company
    • 14.1.13. Glaxosmithkline PLC
    • 14.1.14. Grunenthal Group
    • 14.1.15. Johnson & Johnson Services, Inc.
    • 14.1.16. Merck & Co. Inc.
    • 14.1.17. Novartis AG
    • 14.1.18. Pfizer Inc.
    • 14.1.19. Regeneron Pharmaceuticals Inc.
    • 14.1.20. Sanofi SA
    • 14.1.21. Scilex Pharmaceuticals
    • 14.1.22. Teva Pharmaceutical Industries Ltd.
    • 14.1.23. Trevena Inc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing